The effect of ipragliflozin on ectopic fat accumulation in non-obese type 2 diabetic patients with increased visceral fat

Trial Profile

The effect of ipragliflozin on ectopic fat accumulation in non-obese type 2 diabetic patients with increased visceral fat

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Ipragliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Feb 2017 Status changed from recruiting to completed.
    • 20 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top